(117 days)
Not Found
No
The document describes a vital signs monitoring system and a secondary notification system. There is no mention of AI or ML in the intended use, device description, or performance studies. The testing described focuses on usability, software verification/validation, and alarm performance, not on the training or evaluation of an AI/ML model.
No.
The device is solely for monitoring vital signs and does not describe any therapeutic function or intervention.
Yes.
The device is strictly for monitoring vital signs in adult patients (18 years or older) and provides information such as heart rate, blood pressure, oxygen saturation, and temperature; it does not explicitly state it can diagnose any medical conditions or diseases.
No
The device description explicitly mentions a "lightweight, body-worn vital signs monitor featuring a high resolution, full color touch screen display" and the system is described as capable of measuring various physiological parameters, indicating the presence of hardware components beyond just software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are devices used to examine specimens taken from the human body, such as blood, urine, or tissue, to provide information for diagnosis, monitoring, or screening.
- Device Function: The ViSi Mobile Monitoring System is described as a body-worn vital signs monitor that continuously and non-invasively measures physiological parameters like ECG, heart rate, SpO2, blood pressure, respiration rate, and temperature. It does not analyze specimens taken from the body.
- Intended Use: The intended use is for monitoring vital signs of adult patients in a hospital setting. This is a direct measurement of physiological functions, not an analysis of biological samples.
Therefore, the ViSi Mobile Monitoring System falls under the category of a patient monitoring device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The ViSi Mobile Monitoring System is intended for use by clinicians and medically qualified personnel for single or multi-parameter vital signs monitoring of adult patients (18 years or older). It is indicated for ECG (3 or 5 lead-wire), respiration rate (RESP), heart rate (HR), noninvasive blood pressure (NIBP), continuous noninvasive blood pressure (cNIBP), noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in hospital-based facilities; including, general medical-surgical floors, intermediate care floors, and emergency departments.
The ViSi Mobile Monitoring System may be used as standalone devices or networked to ViSi Mobile Remote Viewers through wireless 802.11 communication.
The ViSi Mobile InSight is an optional secondary notification system that communicates alarms directly to an assigned caregiver. It is intended to supplement the primary alarming devices which originate in the ViSi Mobile patient worn device.
Product codes (comma separated list FDA assigned to the subject device)
MWI, DRT, DXN, DQA, FLL, MSX
Device Description
The ViSi Mobile Monitoring System is a lightweight, body-worn vital signs monitor featuring a high resolution, full color touch screen display, with visual and audible alarms and alerts. The ViSi Mobile Monitor is designed to continuously non-invasively measure ECG, heart rate, SpO2, blood pressure, pulse rate, respiration rate, and temperature. The ECG, SpO2, and Respiration waveforms are viewable on demand. The ViSi Mobile Monitoring System is capable of one-time and continuous NIBP measurements.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adult patients (18 years or older)
Intended User / Care Setting
clinicians and medically qualified personnel / hospital-based facilities; including, general medical-surgical floors, intermediate care floors, and emergency departments.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Performance testing of ViSi Mobile InSight was done in three phases - Human Factors testing, verification testing and validation testing.
Human factors testing: Clinicians already familiar with the ViSi Mobile System but not ViSi Mobile InSight were asked to answer a series of questions and to perform a series of interactive tasks. The testing was proctored by Sotera employees and utilized simulators to annunciate alarms; no patients were used as a part of this testing. At the conclusion of the questions/tasks, each participant was interviewed to provide feedback on ViSi Mobile InSight.
Verification activities: Completion of code reviews and unit testing. Unit tests were completed on both software components of ViSi Mobile InSight by sending mock-up data into methods and checking the output of these methods against the expected output. These tests were performed for each build compiled.
Validation testing: All test steps within the validation protocol passed.
Performance testing was also completed in an intended-use hospital environment with the primary ViSi System under full-load (64 ViSi Wrist Transceivers connected to the RVD/PDS) to characterize alarm receipt and alarm latency periods for the ViSi InSight secondary alarm notification system.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Performance Testing of ViSi Mobile InSight was done in three phases - Human Factors testing, verification testing and validation testing.
Human Factors testing: Overall, the results of the testing satisfied the defined acceptance criteria and validated that proper human factors design was used in the development of ViSi Mobile InSight.
Verification testing: The results all passed.
Validation testing: All test steps within the validation protocol passed.
Performance testing: Under full-load (64 ViSi Wrist Transceivers connected to the RVD/PDS) to characterize alarm receipt and alarm latency periods for the ViSi InSight secondary alarm notification system.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three human profiles incorporated into its design. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 14, 2015
Sotera Wireless, Inc % Mark Job Official Correspondent Regulatory Technology Services, LLC 1394 25th Street, NW Buffalo, Minnesota 55313
Re: K152341
Trade/Device Name: Visi Mobile Monitoring System Regulation Number: 21 CFR 870.2300 Regulation Name: Cardiac Monitor (Including Cardiotachometer and Rate Alarm) Regulatory Class: Class II Product Code: MWI, DRT, DXN, DQA, FLL, MSX Dated: October 21, 2015 Received: October 22, 2015
Dear Mark Job:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
FDA
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name ViSi Mobile Monitoring System
Indications for Use (Describe)
The ViSi Mobile Monitoring System is intended for use by clinicians and medically qualified personnel for single or multi-parameter vital signs monitoring of adult patients (18 years or older). It is indicated for ECG (3 or 5 lead-wire), respiration rate (RESP), heart rate (HR), noninvasive blood pressure (NIBP), continuous noninvasive blood pressure (cNIBP), noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in hospital-based facilities; including, general medical-surgical floors, intermediate care floors, and emergency departments.
The ViSi Mobile Monitoring System may be used as standalone devices or networked to ViSi Mobile Remote Viewers through wireless 802.11 communication.
The ViSi Mobile InSight is an optional secondary notification system that communicates alarms directly to an assigned caregiver. It is intended to supplement the primary alarming devices which originate in the ViSi Mobile patient worn device.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ----------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
6 510(K) SUMMARY
| Date prepared | December 11, 2015 |
|---|---|
| Name | Sotera Wireless, Inc. |
| 10020 Huennekens St | |
| San Diego, CA 92121 | |
| T. 858.427.4620; F. 858.999.2487 | |
| Contact Name | Carson Krupp |
| Trade name | ViSi Mobile Monitoring System |
| Common name | Vital signs monitor |
| Regulation Name | Cardiac Monitor Including Cardiotachometer and Rate Alarm |
| Classification number | 21 CFR 870.2300 |
| Classification Product | |
| Code | MWI |
| Subsequent Product | |
| Codes | DRT, DXN, DQA, FLL, MSX |
| Regulatory class | II |
| Predicate devices | ViSi Mobile Monitoring System; K143751 (Clearance: 01/23/2015) |
| EXTENSION Clinical Alert Notification System; K130339 (Clearance: | |
| 07/11/2013) | |
| Description | The ViSi Mobile Monitoring System is a lightweight, body-worn vital signs monitor featuring a high resolution, full color touch screen display, with visual and audible alarms and alerts. The ViSi Mobile Monitor is designed to continuously non-invasively measure ECG, heart rate, SpO2, blood pressure, pulse rate, respiration rate, and temperature. The ECG, SpO2, and Respiration waveforms are viewable on demand. The ViSi Mobile Monitoring System is capable of one-time and continuous NIBP measurements. |
| Indications for use | The ViSi Mobile Monitoring System is intended for use by clinicians and medically qualified personnel for single or multi-parameter vital signs monitoring of adult patients (18 years or older). It is indicated for ECG (3 or 5 lead-wire), respiration rate (RESP), heart rate (HR), noninvasive blood pressure (NIBP), continuous noninvasive blood pressure (cNIBP), noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in hospital-based facilities; including, general medical-surgical floors, intermediate care floors, and emergency departments. |
4
The ViSi Mobile Monitoring System may be used as standalone devices or networked to ViSi Mobile Remote Viewers through wireless 802.11 communication.
The ViSi Mobile InSight is an optional secondary notification system that communicates alarms directly to an assigned caregiver. It is intended to supplement the primary alarming devices which originate in the ViSi Mobile patient worn device.
Summary of The previously cleared (K143751) ViSi Mobile Monitoring System ("ViSi Substantial System") distributed alarming system has been modified to allow an assigned-Equivalence caregiver-response with respect to annunciated alarms through the utilization of ViSi Mobile InSight. Previously, the Patient Data Server (PDS) would only distribute alarm notifications to the Remote Viewing Device (RVD). From the RVD, an operator could confirm receipt of the alarm through the use of an "Acknowledgement." In the modified system, the PDS will still send the alarm to the RVD and will also secondarily distribute the alarm notifications to assigned caregivers on network-connected mobile devices configured with ViSi Mobile InSight. Once received, the operator will be able to "Accept" or "Decline" the alarm. Accepting the alarm will silence the annunciation on both the mobile device and the RVD, albeit temporarily, and declining the alarm will redirect the annunciation to the next operator in a predefined pathway. In both cases, the response will constitute a confirmed delivery of the alarm notification.
The user response and redirection pathway functionality described above for the ViSi System with ViSi Mobile InSight is similar to that of EXTENSION's Clinical Alert Notification System (K130339) in that both provide a secondary means of alarming for patients on configurable mobile devices in which the user can "Accept" or "Decline" alarms, the latter initiating an alarm redirection pathway. However, EXTENSION's system is on a closed-loop and does not directly interact with the monitoring system supplying the alarms.
The ViSi Mobile Monitoring System with ViSi Mobile InSight will provide an end-to-end solution for distributed alarms. That is, alarms originating from the patient worn device are communicated through the ViSi Mobile PDS to a mobile device carried by a caregiver assigned to the patient. The caregiver can accept the alarm (which effectively silences it) or redirect the alarm to another caregiver by declining or ignoring.
The risk analysis determined that the risk for the ViSi System is not appreciably altered by the implementation of the additional features and is intended to provide medical personnel with information that will have a positive effect on patient safety by integrating alarm notification into their routine work-flow. The risk analysis concluded that the benefits in overall patient safety outweighed the risks and therefore the implementation of ViSi Mobile InSight is worthwhile.
The ViSi System's device design, technology, materials, processes, etc. have not been changed with this application. The modification is only to add the aforementioned ViSi Mobile InSight capability to the intended use; therefore the
5
ViSi Mobile Monitoring System as described in this submission is substantially equivalent to the predicate ViSi System (K143751).
Summary of Non-Clinical Performance Testing of ViSi Mobile InSight was done in three Performance Testing phases - Human Factors testing, verification testing and validation testing. Human factors testing was completed to assess both the usability and readability of ViSi Mobile InSight. For the testing, clinicians already familiar with the ViSi Mobile System but not ViSi Mobile InSight were asked to answer a series of questions and to perform a series of interactive tasks. The testing was proctored by Sotera employees and utilized simulators to annunciate alarms; no patients were used as a part of this testing. At the conclusion of the questions/tasks, each participant was interviewed to provide feedback on ViSi Mobile InSight. Overall, the results of the testing satisfied the defined acceptance criteria and validated that proper human factors design was used in the development of ViSi Mobile InSight.
Verification activities included the completion of code reviews and unit testing. Unit tests were completed on both software components of ViSi Mobile InSight by sending mock-up data into methods and checking the output of these methods against the expected output. These tests were performed for each build compiled and the results all passed.
Validation testing was completed to ensure that all software requirements were met and performed as intended. All test steps within the validation protocol passed.
Performance testing was also completed in an intended-use hospital environment with the primary ViSi System under full-load (64 ViSi Wrist Transceivers connected to the RVD/PDS) to characterize alarm receipt and alarm latency periods for the ViSi InSight secondary alarm notification system.